Conference
Phase I study of daily oral AZD 2171, an inhibitor of the vascular endothelial growth factor receptor (VEGFR), in combination with carboplatin/paclitaxel in patients with advanced non-small cell lung cancer (NSCLC): A study of the NCICCTG.
Authors
Laurie SA; Arnold A; Gauthier I; Ellis P; Goss G; Chen E; Shepherd F; Fisher B; Robertson J; Seymour L
Volume
11
Pagination
pp. 8970S-8970S
Publisher
AMER ASSOC CANCER RESEARCH
Publication Date
December 15, 2005
Name of conference
AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics
Conference place
PA, Philadelphia
Conference start date
November 14, 2005
Conference end date
November 18, 2005
Conference proceedings
CLINICAL CANCER RESEARCH
Issue
24
ISSN
1078-0432